We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+46.74%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.57B
AUM Growth
+$1.21B
Cap. Flow
+$318M
Cap. Flow %
8.9%
Top 10 Hldgs %
45.04%
Holding
142
New
39
Increased
22
Reduced
59
Closed
10

Top Buys

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$68.1M
2
GBIO
Generation Bio
GBIO
+$62.7M
3
RPRX icon
Royalty Pharma
RPRX
+$37.1M
4
ONC
BeOne Medicines Ltd
ONC
+$32.6M
5
NG icon
NovaGold Resources
NG
+$26.3M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$137M
2
AVTR icon
Avantor
AVTR
+$40.7M
3
PYPL icon
PayPal
PYPL
+$33.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27M
5
Z icon
Zillow
Z
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 61.98%
2 Consumer Discretionary 13.38%
3 Technology 3.16%
4 Financials 1.15%
5 Communication Services 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$376M 10.52%
14,818,300
– –
JPM icon
2
CALL
JPMorgan Chase
JPM
$929B
$282M 7.9%
+3,000,000
New +$285M
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
$160M 4.48%
850,000
+200,000
+31% +$32.6M
BNTX icon
4
BioNTech
BNTX
$23.4B
$133M 3.73%
2,000,000
-228,130
-10% -$11.4M
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$133M 3.73%
1,400,000
-100,000
-7% -$9.64M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$38.4B
$133M 3.73%
900,000
-200,000
-18% -$27M
LXRX icon
7
Lexicon Pharmaceuticals
LXRX
$1.03B
$120M 3.36%
60,240,864
– –
ARGX icon
8
argenx
ARGX
$55.1B
$101M 2.84%
450,000
-25,000
-5% -$4.44M
GDS icon
9
GDS Holdings
GDS
$5.98B
$87.6M 2.45%
+1,100,000
New +$68.1M
SDGR icon
10
Schrodinger
SDGR
$1.12B
$82.2M 2.3%
897,445
– –
BABA icon
11
Alibaba
BABA
$275B
$80.3M 2.25%
372,500
-27,500
-7% -$5.73M
BDTX icon
12
Black Diamond Therapeutics
BDTX
$98.6M
$65.2M 1.82%
1,546,517
-150,000
-9% -$5.52M
FATE icon
13
Fate Therapeutics
FATE
$267M
$61.8M 1.73%
1,800,000
-300,000
-14% -$8.94M
GBIO
14
DELISTED
Generation Bio
GBIO
$59.1M 1.65%
+281,419
New +$62.7M
ALXN
15
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$56.1M 1.57%
+500,000
New +$53.1M
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
$52.8M 1.48%
3,500,000
-1,500,000
-30% -$18.3M
C icon
17
CALL
Citigroup
C
$216B
$51.1M 1.43%
+1,000,000
New +$47.4M
SRRK icon
18
Scholar Rock
SRRK
$5.88B
$46M 1.29%
2,524,040
-22,000
-0.9% -$375K
MORF
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$45.2M 1.26%
1,669,186
-150,000
-8% -$2.81M
QURE icon
20
uniQure
QURE
$2.71B
$45.1M 1.26%
1,000,000
-150,000
-13% -$8.86M
BPMC
21
DELISTED
Blueprint Medicines
BPMC
$42.9M 1.2%
550,000
+150,000
+38% +$10.1M
GS icon
22
CALL
Goldman Sachs
GS
$293B
$39.5M 1.11%
+200,000
New +$37.5M
DCPH
23
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$38.8M 1.09%
650,000
-150,000
-19% -$8.02M
ATRA icon
24
Atara Biotherapeutics
ATRA
$70.4M
$36.4M 1.02%
100,000
– –
RPRX icon
25
Royalty Pharma
RPRX
$26.6B
$36.4M 1.02%
+750,000
New +$37.1M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2020 Portfolio in Review

As of Q2 2020, Artal Group held 142 positions worth $3.57B, up 51% from $2.37B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group deployed $318M of net new capital in Q2 2020, opening 39 new positions and adding to 22 existing holdings. Its largest new stake was GDS Holdings: 1,100,000 shares worth $87.6M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 69% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Moderna, an estimated $137M trimmed.

  • Artal Group's largest Q2 2020 buy was GDS Holdings: 1,100,000 shares worth $87.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q2 2020, an estimated $32.6M increase.
  • Artal Group's biggest Q2 2020 reduction was Moderna, cutting an estimated $137M.
  • Artal Group fully exited Arrowhead Research in Q2 2020, selling an estimated $17.3M.
  • Artal Group's ten largest holdings make up 45% of its $3.57B portfolio in Q2 2020.
  • Artal Group opened 39 new positions and closed 10 in Q2 2020.
  • Artal Group's portfolio value rose 51% quarter-over-quarter to $3.57B.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.